EXEL — Exelixis Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $72.77
- YTD price return
- +66.03%
- YTD total return
- +66.03%
- Market cap
- 17.8B
- Enterprise value
- 17.1B
- Shares outstanding
- 244M
- 52W low
- $37.58
- 52W high
- $73.44
- From 52W high
- -0.91%
- From 52W low
- +93.64%
- 52W range
- 98%$37.58–$73.44
- Beta
- 0.41
Volume
- Rel volume
- 2.18×
- 30D volume
- 2.6M
- 30D $ vol
- 163.8M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$527K
- Insider net 1Y
- −$31.8M
Form 4 transactions by trade date, as filed; latest on file 2026-08-10.
Fundamentals
- Sales (ttm)
- 2.5B
- Sales/share
- $10.23
- EPS (ttm)
- $3.34
- FCF (ttm)
- 1.2B
- FCF/share
- $4.76
- Book value/share
- $7.52
- Net margin
- 35.45%
- ROE
- 48.27%
- ROA
- 35.22%
- Current ratio
- 3.21
Growth (CAGR, ttm) · 10Y
- Sales
- +9.15%+12.02%+14.76%+35.02%
- Net income
- +30.69%+112.16%+40.03%n/a
- FCF
- +49.11%+47.66%+33.36%+29.28%
- Shares
- -9.02%-7.74%-5.06%-1.59%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +41.28%+126.98%+45.63%n/a
- Sales/share
- +19.97%+21.42%+20.88%+37.21%
- FCF/share
- +63.89%+60.05%+40.47%+31.37%
- Book value/share
- -6.77%-0.15%+2.39%+52.29%
- Price
- +92.09%+51.25%+30.91%+21.71%
- Total return
- +92.09%+51.25%+30.91%+21.71%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 21.8×
- P/OI (ttm)
- 17.7×
- Fwd P/E
- 16.7×
- P/S (ttm)
- 7.1×
- P/B (mrq)
- 9.7×
- P/FCF (ttm)
- 15.3×
- EV/EBITDA (fy)
- 16.5×
- EV/Sales (ttm)
- 6.8×
- FCF yield (ttm)
- 6.54%
- Buyback yield (realized, 1y)
- 9.02%
- Shareholder yield (realized, 1y)
- 9.02%
- Buyback yield (cash, ttm)
- 7.10%
- Shareholder yield (cash, ttm)
- 7.10%
Vs own 10Y history
- P/E
- 42nd
- P/OI
- 42nd
- P/S
- 69th
- P/B
- 86th
- P/FCF
- 30th
Bar = where today’s multiple sits in EXEL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-04#
Fundamentals#
Operating income
5Y CAGR +51.3%10Y n/mYoY +13.5%EPS (diluted)
5Y CAGR +51.4%10Y n/mYoY +23.2%Free cash flow
5Y CAGR +37.4%10Y n/mYoY −3.9%TTM: operating cash flow $1.2B, capex −$12M
Q3 2026: operating cash flow $280M, capex −$2.5M
Shares (diluted)
5Y −11.4%10Y +34.7%YoY −8.2%Net income
5Y CAGR +47.6%10Y n/mYoY +12.7%About Exelixis#
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.
Alameda, CA·1,077 employees·Biotechnology·exelixis.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS $0.85 vs $0.79 est. (+7.6%); revenue $658.7M (+10% y/y) 4.8%
- Aug 5Earnings · Earnings release — EPS $0.82 vs $0.75 est. (+9.3%); revenue $628.7M (+11% y/y) 7.9%
ETFs holding EXEL#
25 of the 193 ETFs ChartRow carries live hold EXEL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.0% |
| XBI | SPDR S&P Biotech ETF | 1.0% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.4% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.4% |
| VBK | Vanguard Small-Cap Growth ETF | 0.4% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.2% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |
